In which patients with acute myeloid leukemia (AML) does hematopoietic stem cell transplantation (HCT) offer a survival advantage?

Updated: May 26, 2020
  • Author: Karen Seiter, MD; Chief Editor: Emmanuel C Besa, MD  more...
  • Print

The American Society for Blood and Marrow Transplantation (ASBMT) considers that in patients with AML who are under age 55, allogeneic HCT offers no survival advantage for those with low-risk cytogenetics who are in first clinical remission, but does offer a survival advantage versus chemotherapy for those with high-risk cytogenetics. [53]

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!